Browse TPM2

Summary
SymbolTPM2
Nametropomyosin 2 (beta)
Aliases NEM4; nemaline myopathy type 4; AMCD1; arthrogryposis multiplex congenital, distal, type 1; HEL-S-273; TMSB; ......
Chromosomal Location9p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytoskeleton Note=Associates with F-actin stress fibers.
Domain PF00261 Tropomyosin
Function

Binds to actin filaments in muscle and non-muscle cells. Plays a central role, in association with the troponin complex, in the calcium dependent regulation of vertebrate striated muscle contraction. Smooth muscle contraction is regulated by interaction with caldesmon. In non-muscle cells is implicated in stabilizing cytoskeleton actin filaments. The non-muscle isoform may have a role in agonist-mediated receptor internalization.

> Gene Ontology
 
Biological Process GO:0003012 muscle system process
GO:0006936 muscle contraction
GO:0030048 actin filament-based movement
GO:0030049 muscle filament sliding
GO:0033275 actin-myosin filament sliding
GO:0043462 regulation of ATPase activity
GO:0070252 actin-mediated cell contraction
Molecular Function GO:0003779 actin binding
GO:0008307 structural constituent of muscle
Cellular Component GO:0005862 muscle thin filament tropomyosin
GO:0005865 striated muscle thin filament
GO:0015629 actin cytoskeleton
GO:0030016 myofibril
GO:0030017 sarcomere
GO:0036379 myofilament
GO:0043292 contractile fiber
GO:0044449 contractile fiber part
> KEGG and Reactome Pathway
 
KEGG hsa04260 Cardiac muscle contraction
hsa04261 Adrenergic signaling in cardiomyocytes
Reactome R-HSA-397014: Muscle contraction
R-HSA-445355: Smooth Muscle Contraction
R-HSA-390522: Striated Muscle Contraction
Summary
SymbolTPM2
Nametropomyosin 2 (beta)
Aliases NEM4; nemaline myopathy type 4; AMCD1; arthrogryposis multiplex congenital, distal, type 1; HEL-S-273; TMSB; ......
Chromosomal Location9p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TPM2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolTPM2
Nametropomyosin 2 (beta)
Aliases NEM4; nemaline myopathy type 4; AMCD1; arthrogryposis multiplex congenital, distal, type 1; HEL-S-273; TMSB; ......
Chromosomal Location9p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TPM2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTPM2
Nametropomyosin 2 (beta)
Aliases NEM4; nemaline myopathy type 4; AMCD1; arthrogryposis multiplex congenital, distal, type 1; HEL-S-273; TMSB; ......
Chromosomal Location9p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TPM2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.2320.0167
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-2.3020.388
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4590.829
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.7760.292
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3940.905
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.2620.76
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0880.87
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2510.884
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0470.98
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0660.978
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3080.682
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3360.038
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TPM2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTPM2
Nametropomyosin 2 (beta)
Aliases NEM4; nemaline myopathy type 4; AMCD1; arthrogryposis multiplex congenital, distal, type 1; HEL-S-273; TMSB; ......
Chromosomal Location9p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TPM2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTPM2
Nametropomyosin 2 (beta)
Aliases NEM4; nemaline myopathy type 4; AMCD1; arthrogryposis multiplex congenital, distal, type 1; HEL-S-273; TMSB; ......
Chromosomal Location9p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TPM2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TPM2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTPM2
Nametropomyosin 2 (beta)
Aliases NEM4; nemaline myopathy type 4; AMCD1; arthrogryposis multiplex congenital, distal, type 1; HEL-S-273; TMSB; ......
Chromosomal Location9p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TPM2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTPM2
Nametropomyosin 2 (beta)
Aliases NEM4; nemaline myopathy type 4; AMCD1; arthrogryposis multiplex congenital, distal, type 1; HEL-S-273; TMSB; ......
Chromosomal Location9p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TPM2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTPM2
Nametropomyosin 2 (beta)
Aliases NEM4; nemaline myopathy type 4; AMCD1; arthrogryposis multiplex congenital, distal, type 1; HEL-S-273; TMSB; ......
Chromosomal Location9p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TPM2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTPM2
Nametropomyosin 2 (beta)
Aliases NEM4; nemaline myopathy type 4; AMCD1; arthrogryposis multiplex congenital, distal, type 1; HEL-S-273; TMSB; ......
Chromosomal Location9p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TPM2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.